Drawing based on the label description. No photo yet.
“RINVOQ 30 mg extended-release tablets for oral administration are red, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with 'a30' on one side”
a30 pill
Pill with imprint a30 is red, capsule, 14 mm and has been identified as Upadacitinib 30 mg. It is used for rheumatoid arthritis. It is supplied by Abbvie Inc.
Upadacitinib 30 mg
- Imprint
- a30
- Strength
- 30 mg
- Used for
- Rheumatoid arthritis
- Color
- Red
- Shape
- Capsule / oblong
- Size
- 14 mm
- Score
- No score line
- Form
- Tablet, extended release
- Manufacturer
- Abbvie Inc
- Drug class
- Cancer medicine (kinase inhibitor)
- NDC
- 0074-2310, 0074-2310-30, 0074-2310-20
Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .
Report a mistake
What is Upadacitinib used for?
Upadacitinib is used for rheumatoid arthritis.
- Medicine type
- Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label
Rheumatoid Arthritis
RINVOQ® is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.
Psoriatic Arthritis
RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
- Limitations of Use: RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
Atopic Dermatitis
RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.
Ulcerative Colitis
RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more TNF blockers. If TNF blockers are clinically inadvisable, patients should have received at least one approved systemic therapy prior to use of RINVOQ.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for UC, or with potent immunosuppressants such as azathioprine and cyclosporine.
Crohn’s Disease
RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease (CD) who have had an inadequate response or intolerance to one or more TNF blockers. If TNF blockers are clinically inadvisable, patients should have received at least one approved systemic therapy prior to use of RINVOQ.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for CD, or with potent immunosuppressants such as azathioprine and cyclosporine.
. 6 Ankylosing Spondylitis
RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
. 7 Non-radiographic Axial Spondyloarthritis
RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
Polyarticular Juvenile Idiopathic Arthritis
RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an inadequate response or intolerance to one or more TNF blockers.
- Limitations of Use: RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
Giant Cell Arteritis
RINVOQ is indicated for the treatment of adults with giant cell arteritis.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
From the FDA-approved label on DailyMed (published Jul 15, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your pill? Check every detail
- One side shows a30 and the other side has no imprint.
- It is red, capsule, 14 mm.
- Its score line and coating match the details on this page.
- It came from a pharmacy package that names the same drug.
Sold under the brand name Rinvoq.
Ingredients
Active: Upadacitinib
Inactive: Silicon Dioxide, Hypromellose, Unspecified, Ferric Oxide Red, Magnesium Stearate, Mannitol, Microcrystalline Cellulose, Polyvinyl Alcohol, Unspecified, Polyethylene Glycol, Unspecified, Talc, Tartaric Acid, Titanium Dioxide
Other pills with imprint A 30
Same imprint, different listing. Check the color, size and maker against your pill.
- A30 Afatinib Dimaleate 30 mg White, round Used for lung cancer and squamous cell carcinoma
- A30 Aripiprazole 30 mg Pink, round, 9 mm Used for schizophrenia
- A30 Atogepant 30 mg White, oval, 7 mm Used for migraine
- A30 Butalbital, Acetaminophen and Caffeine 50 mg / 325 mg / 40 mg White, capsule, 21 mm Used for headache Schedule III
- A 30 Carvedilol 12.5 mg White, oval, 10 mm Used for high blood pressure and heart failure
- a30 Upadacitinib 30 mg Red, capsule, 8 mm Used for rheumatoid arthritis
Pills that look similar but are different drugs
Same color and shape, different medicine. This is why the imprint matters.
-
G 687
Tacrolimus 5 mg
Red, capsule, 14 mm
Used for eczema
-
B30
Cyclobenzaprine Hydrochloride 30 mg
Blue & red, capsule, 14 mm
Used for muscle stiffness (spasticity) and muscle spasms
-
LA 43
Pregabalin 75 mg
Red & white, capsule, 14 mm
Used for seizures and nerve pain after shingles
Schedule V
-
5MG RDY527
Tacrolimus 5 mg
Red, capsule, 14 mm
Used for eczema
-
R 069
Oxazepam 15 mg
Red, capsule, 14 mm
Used for anxiety and focal seizures
Schedule IV
- Cipla 03050mg Nilotinib 50 mg Red, capsule, 15 mm Used for accelerated phase myeloid leukemia and chronic-phase myeloid leukemia
Other Upadacitinib pills
- a15 Upadacitinib 15 mg Purple, capsule, 14 mm Used for rheumatoid arthritis
- a15 Upadacitinib 15 mg Purple, capsule, 8 mm Used for rheumatoid arthritis
- a45 Upadacitinib 45 mg Yellow, capsule, 14 mm Used for rheumatoid arthritis
- a45 Upadacitinib 45 mg Yellow, capsule, 8 mm Used for rheumatoid arthritis